Abstract
Matrix metalloproteinases (MMPs), also designated as matrixins, play a central role in many biological processes and are involved both in physiologic cellular processes and in pathologic situations such as tumor growth, invasion and metastasis. For more than 30 years MMPs have been considered as promising targets for cancer therapy and a number of different synthetic and natural MMP inhibitors have been identified as cytostatic and anti-angiogenic agents and have begun clinical testing in view of their specific implication in malignant tissues. Although preclinical studies were so compelling to encourage several clinical trials, the past years have seen a consistent number of disappointments and limited success. The critical examination of previous studies shed light on new information about the cellular source, substrates and mode of action of MMPs, focusing the attention of future research on the identification of specific MMP targets in tumors at different stage of tumor progression, both in order to improve efficacy and to reduce the side effect profile. In this review we discuss the current view on the feasibility of MMPs as target for therapeutic intervention in cancer, taking into account that the perspective may be of great value for molecular medicine for the twenty-first century, providing intriguing information about the MMPs as mediators in biology and pathology, and as targets for disease therapies.
Keywords: matrix metalloproteinases, gelatinases, cancer, protease inhibitors, therapeutic strategies, clinical trials
Current Cancer Drug Targets
Title: Matrix Metalloproteinase Inhibitors as Anticancer Therapeutics
Volume: 5 Issue: 4
Author(s): F. Mannello, G. Tonti and S. Papa
Affiliation:
Keywords: matrix metalloproteinases, gelatinases, cancer, protease inhibitors, therapeutic strategies, clinical trials
Abstract: Matrix metalloproteinases (MMPs), also designated as matrixins, play a central role in many biological processes and are involved both in physiologic cellular processes and in pathologic situations such as tumor growth, invasion and metastasis. For more than 30 years MMPs have been considered as promising targets for cancer therapy and a number of different synthetic and natural MMP inhibitors have been identified as cytostatic and anti-angiogenic agents and have begun clinical testing in view of their specific implication in malignant tissues. Although preclinical studies were so compelling to encourage several clinical trials, the past years have seen a consistent number of disappointments and limited success. The critical examination of previous studies shed light on new information about the cellular source, substrates and mode of action of MMPs, focusing the attention of future research on the identification of specific MMP targets in tumors at different stage of tumor progression, both in order to improve efficacy and to reduce the side effect profile. In this review we discuss the current view on the feasibility of MMPs as target for therapeutic intervention in cancer, taking into account that the perspective may be of great value for molecular medicine for the twenty-first century, providing intriguing information about the MMPs as mediators in biology and pathology, and as targets for disease therapies.
Export Options
About this article
Cite this article as:
Mannello F., Tonti G. and Papa S., Matrix Metalloproteinase Inhibitors as Anticancer Therapeutics, Current Cancer Drug Targets 2005; 5 (4) . https://dx.doi.org/10.2174/1568009054064615
DOI https://dx.doi.org/10.2174/1568009054064615 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Chemical Characterization of N10-Substituted Acridones as Reversers of Multidrug Resistance in Cancer Cells
Letters in Drug Design & Discovery Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Basics in Endoscopic Ultrasound Part 2: EUS-guided Sampling and Therapeutic Applications
Reviews on Recent Clinical Trials Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ]
Current Cancer Drug Targets Branched Peptides as Therapeutics
Current Protein & Peptide Science Bioactive Sterol Derivatives Isolated from the <i>Pleurotus djamor</i> var. Roseus Induced Apoptosis in Cancer Cell Lines
Cardiovascular & Hematological Agents in Medicinal Chemistry Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D
Mini-Reviews in Medicinal Chemistry Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
Current Medicinal Chemistry Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Melatonin, Immune Function and Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lectin Techniques for Glycoproteomics
Current Proteomics Application of 3-methylene- and 3-(monosubstituted)alkylideneoxindoles in the Synthesis of Heterocyclic Compounds
Current Organic Chemistry Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Functional Nanogels for Biomedical Applications
Current Medicinal Chemistry Tracking Cell Signaling Protein Expression and Phosphorylation by Innovative Proteomic Solutions
Current Pharmaceutical Biotechnology Nanoradiopharmaceuticals: Is that the Future for Nuclear Medicine?
Current Radiopharmaceuticals Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Current Medicinal Chemistry Immunopharmacological Activity of Betulin in Inflammation-associated Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets